Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1625011

registered interest
date	27/04/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Life Sciences: Investment
house id	1
legislature	25259 pref label House of Commons
question text	What steps her Department is taking to support investment in the life sciences industry.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	904759
answer	answer is ministerial correction date of answer 12/05/2023 answer text <p>The Life Sciences Vision set a strategic goal to make the UK the most attractive location in Europe to start and grow a Life Sciences Business.</p><p>This Government is driving the largest increase in public R&amp;D in the UK for a generation – from £15bn a year to £20bn a year in the next three years, and to £22bn a year in 2027.</p><p>In March DSIT announced £17m of grant funding from the Life Sciences Innovative Manufacturing Fund (LSIMF), securing £260 million of private investment.</p><p> </p><p>At the Spring Budget the Chancellor announced Capital Allowance reforms which introduced a full expensing 100% first year allowance worth £27 billion over 3 years.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/05/2023 10:16:27 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

520785

registered interest
date	23/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Strokes: Aspirin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with medical organisations on the use of aspirin to prevent strokes.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	38111
answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>The National Institute for Health and Care Excellence’s (NICE) clinical guideline on stroke and transient ischaemic attack in over 16s: diagnosis and initial management (CG68), published in July 2008, recommends that all people presenting with acute stroke who have had a diagnosis of primary intracerebral haemorrhage excluded by brain imaging should be given aspirin 300 mg as soon as possible but certainly within 24 hours.</p><p> </p><p>Thereafter, aspirin 300 mg should be continued until two weeks after the onset of stroke symptoms, at which time definitive long-term antithrombotic treatment should be initiated.</p><p> </p><p> </p><p>This guidance is due to be reviewed by NICE in July 2016 to see whether it needs to be updated.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/05/2016 13:41:31 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

390818

registered interest
date	16/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Leukaemia: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that patients with chronic myeloid leukaemia in England have access to (a) Ponatinib and (b) other innovative new medicines.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	7658
answer	answer is ministerial correction date of answer 21/07/2015 answer text <p>A number of drugs for the treatment of chronic myeloid leukaemia have been recommended by the National Institute for Health and Care Excellence and are routinely available in England.</p><p> </p><p> </p><p> </p><p>A number of other drugs, including ponatinib, are available through the Cancer Drugs Fund.</p><p> </p><p> </p><p> </p><p>We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2015 11:46:22 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

390820

registered interest
date	16/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effect of potential delays for patients in access to medicines as a result of changes to the National Cancer Drugs Fund in March 2016.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	7656
answer	answer is ministerial correction date of answer 21/07/2015 answer text <p>We have made no such assessment nor have there been any discussions between the Department and the Royal Colleges. The Government is committed to continuing to invest in the Cancer Drugs Fund.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 7657 question first answered 21/07/2015 12:09:01 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

390821

registered interest
date	16/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the Royal Colleges on the future of the National Cancer Drugs Fund beyond March 2016.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	7657
answer	answer is ministerial correction date of answer 21/07/2015 answer text <p>We have made no such assessment nor have there been any discussions between the Department and the Royal Colleges. The Government is committed to continuing to invest in the Cancer Drugs Fund.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 7656 question first answered 21/07/2015 12:09:01 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

222945

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the BMA and other medical bodies on when treatment resistant prostate cancer drugs will be available in light of GPR158.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	224994
answer	answer is ministerial correction date of answer 26/02/2015 answer text <p>My Rt. hon. Friend the Secretary of State for Health has had no such discussions.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/02/2015 11:32:36 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

179005

registered interest
date	10/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ruxolitinib: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information his Department holds on how many people have experienced adverse health effects as a result of using the drug ruxolitinib.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	224109
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines through the spontaneous reporting scheme, the Yellow Card Scheme. The Yellow Card Scheme collects information relating to suspected adverse drug reactions, which include both serious and non-serious effects which a health care professional or patient suspect may have been due to a medicine.</p><p> </p><p> </p><p> </p><p>The MHRA has received a total of 74 United Kingdom spontaneous suspected ADR reports in association with ruxolitinib up to and including 10 February 2015. This number includes reports received directly from healthcare professionals, patients and indirectly through pharmaceutical companies which have a legal obligation to report suspected ADRs.</p><p> </p><p> </p><p> </p><p>The inclusion of a particular ADR in a report does not necessarily mean it has been caused by the drug, only that the reporter had a suspicion it may have, or it had a close temporal relationship to the administration of the suspect drug. The fact that symptoms occur after a treatment does not necessarily mean that they have been caused by the drug itself, as underlying illnesses and other conditions may be responsible.</p><p> </p><p><strong> </strong></p><p> </p><p>In 2013, the product information for ruxolitinib was updated to warn healthcare professionals that cases of progressive multifocal leukoencephalopathy (PML) have been reported with ruxolitinib and to recommend that patients are monitored at regular intervals for any new or worsening neurological symptoms or signs. The Market Authorisation Holder is currently conducting studies to investigate the risk of PML further. The benefits of ruxolitinib to adult patients with myelofibrosis who have an enlarged spleen or symptoms related to the disease are considered to outweigh the risks.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/02/2015 16:21:43 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

167513

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sleeping Pills
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent representations he has received on the prescription of zolpidem.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	216755
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>In the 6 month period, June 2014 to November 2014, the Department received no written representations concerning the prescribing of zolpidem (Stilnoct).</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 12:50:25 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

156298

registered interest
date	18/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dietary Supplements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent research he has commissioned into the health benefits of fish oils.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	214822
answer	answer is ministerial correction date of answer 21/11/2014 answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £1.5 million trial to find out if an omega-3 fatty acid called EPA found naturally in fish oil, on its own or in combination with aspirin, can prevent the development of bowel polyps.</p><p> </p><p><strong> </strong></p><p> </p><p>The NIHR Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London has recently co-funded research published in the journal <em>Biological Psychiatry</em> that found that omega-3 fatty acids reduce the rates of depression among patients with high levels of inflammation.</p><p> </p><p> </p><p> </p><p>The NIHR/Wellcome Trust Imperial Clinical Research Facility is currently hosting a study on whether fish oil helps people to lose weight.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/11/2014 13:33:26 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

100402

registered interest
date	22/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Paralysis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he has taken to support University College London in its work to enable people who have been paralysed to regain the ability to walk.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	211576
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The Department’s National Institute for Health Research (NIHR) funds 11 biomedical research centres that conduct translational research to transform scientific breakthroughs into benefits for patients. These centres are formed through partnerships between England’s leading National Health Service organisations and universities.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £110 million over five years (2012-17) in the NIHR biomedical research centre at University College London Hospitals NHS Foundation Trust and University College London. The centre is supporting research on the use of cells from the lining of the nose to repair damaged nerves in the spinal cord.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2014 16:53:22 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon